L-3,5-dibromo-3'-<(oxo-1,6-dihydropyridazin-3-yl)methyl>thyronine | 105211-23-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-3,5-dibromo-3'-<(oxo-1,6-dihydropyridazin-3-yl)methyl>thyronine
• 英文别名: L-3,5-dibromo-3'-<(6-oxo-1,6-dihydropyridazin-3-yl)methyl>thyronine；L-94901；(S)-2-amino-3-(3,5-dibromo-4-[4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenyoxyl]-phenyl)-propionic acid；SKF 94901；L-3,5-dibromo-3'-(6-oxo-3(1H)-pyridazinylmethyl)-thyronine；3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine；2-Ammonio-3-{3,5-dibromo-4-[4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxy]-phenyl}-propionic acid anion；(2S)-2-amino-3-[3,5-dibromo-4-[4-hydroxy-3-[(6-oxo-1H-pyridazin-3-yl)methyl]phenoxy]phenyl]propanoic acid
• CAS: 105211-23-2
• 化学式: C₂₀H₁₇Br₂N₃O₅
• 分子量: 539.18
• InChiKey: BPCRJQJRJFLQHV-INIZCTEOSA-N

物化性质

• 熔点：
  278-279 °C (decomp)
• 密度：
  1.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  L-3,5-dibromo-3'-<(6-chloropyridazin-3-yl)methyl>-5'-t-butyl-N-trifluoroacetylthyronine methyl ester 在 氢溴酸 、 sodium acetate 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 8.0h， 生成 L-3,5-dibromo-3'-<(oxo-1,6-dihydropyridazin-3-yl)methyl>thyronine
  参考文献：
  名称：

  甲状腺激素类似物的合成。第2部分。SK＆F L-94901的氧化偶联方法

  摘要：

  的合成大号-3,5-二溴-3' - [（6-氧代-1,6-二氢哒嗪-3-基）甲基〕甲状腺原氨酸-SK＆F L-94901（1），一种新型，选择性且有效的仿甲状腺-描述。该合成中的关键步骤涉及受阻二芳基醚部分的形成。本文介绍了一种通过受阻酚（2）和（3）的氧化偶联方法。简要讨论了合成过程中产生的一些副产物和杂质。

  DOI：

  10.1039/p19880003097

文献信息

• Use of src SH2 specific compounds to treat a bone resorption disease
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0727211A1

  公开（公告）日：1996-08-21

  Invented is a method of treating a bone resorption disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human src SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human lck SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such src SH2 domain.

  已发明一种治疗骨吸收疾病的方法，包括向受试者施用与人src SH2结构域结合的化合物的治疗有效量，其结合亲和力比其与人lck SH2结构域和人fyn SH2结构域结合的结合亲和力高出五十倍以上，并且与人hcp SH2结构域、人Grb2 SH2结构域、人SH-PTP2 SH2结构域和人p85 SH2结构域结合的结合亲和力比其与该src SH2结构域结合的结合亲和力低五十倍以上。
• Pyridyl and pyridazinyl substituted thyronine compounds having selective
  申请人：Smith Kline & French Laboratories Ltd.

  公开号：US04766121A1

  公开（公告）日：1988-08-23

  This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.

  这项发明涉及具有选择性甲状腺激素活性的化合物。该发明的一种化合物是3,5-二溴-3'-[6-氧代-3(1H)-吡啶嗪基甲基]-甲状腺氨酸。
• Antidiabetic agents
  申请人：Pfizer Products Inc.

  公开号：EP1340500A1

  公开（公告）日：2003-09-03

  A compound of the formula wherein n, m, Z, R1, R5, R8, R9, R10 and R11 are as defined above, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.

  一种具有上述定义的化合物的分子式，用于治疗糖尿病、胰岛素抵抗、糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变、白内障、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和组织缺血，特别是心肌缺血。
• Malonamic acids and derivatives thereof as thyroid receptor ligands
  申请人：——

  公开号：US20010051657A1

  公开（公告）日：2001-12-13

  The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula 1, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders. 1

  本发明涉及新型甲状腺受体配体，更具体地涉及Formula 1的马隆酰胺酸及其衍生物，可用于治疗肥胖、超重症、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退、甲状腺癌及相关疾病，如糖尿病、动脉粥样硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松症和脱发。本发明还提供了用于治疗此类疾病和疾病的方法、药物组合物和试剂盒。
• Indole carboxylic acids as thyroid receptor ligands
  申请人：——

  公开号：US20030078289A1

  公开（公告）日：2003-04-24

  A compound of the formula 1 wherein W, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.

  一种化合物的公式1，其中W，R1，R2，R3，R4，R5，R6，R7，R8和R13如本文所定义，在治疗肥胖、超重症、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退症、甲状腺癌及相关疾病和疾病（如糖尿病、动脉粥样硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松症和脱发）的治疗中有用。